Also, experimental evidences indicate that drug resistance to VEGF blockade may occur following reactivation of the angiogenic process triggered by the compensatory upregulation of the FGF/FGFR system in experimental tumor models [32] and in cancer patients [33], representing a mechanism of escape to anti-VEGF therapy in cancer treatment [31]. This evidence concerns the gene VEGFA and neoplasm.